Literature DB >> 28230290

A3 Adenosine Receptor Agonist Inhibited Survival of Breast Cancer Stem Cells via GLI-1 and ERK1/2 Pathway.

Seyyed Mehdi Jafari1, Mojtaba Panjehpour1,2, Mahmoud Aghaei1,3, Hamid Reza Joshaghani4, Seyed Ehsan Enderami5.   

Abstract

Numerous studies have demonstrated the role of A3 adenosine receptor (A3AR) and signaling pathways in the multiple aspects of the tumor. However, there is a little study about the function of A3AR in the biological processes of cancer stem cells (CSCs). CSCs have a critical role in the maintenance and survival of breast cancer. The aim of current study was to investigate the effect of A3AR agonist on breast cancer stem cells (BCSCs). XTT assay showed antiproliferative effect of A3AR agonist (Cl-IB-MECA) on BCSCs. Our results also demonstrated that A3AR agonist reduces mammosphere formation in a dose-dependent manner. Flow cytometry analysis showed that A3AR agonist induces G1 cell cycle arrest and apoptosis in BCSCs. Western blot assay showed that A3AR agonist inhibits the expression of cell cycle and apoptotic regulatory proteins as well as the expression of ERK1/2 and GLI-1 proteins. Finally, these findings propose that A3AR agonist induces cell cycle arrest and apoptosis in BCSCs by inhibition of ERK1/2 and GLI-1 cascade. J. Cell. Biochem. 118: 2909-2920, 2017.
© 2017 Wiley Periodicals, Inc. © 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  A3 ADENOSINE RECEPTOR; BREAST CANCER STEM CELLS; ERK1/2; GLI-1

Mesh:

Substances:

Year:  2017        PMID: 28230290     DOI: 10.1002/jcb.25945

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  11 in total

1.  A2B adenosine receptor agonist induces cell cycle arrest and apoptosis in breast cancer stem cells via ERK1/2 phosphorylation.

Authors:  Seyyed Mehdi Jafari; Hamid Reza Joshaghani; Mojtaba Panjehpour; Mahmoud Aghaei
Journal:  Cell Oncol (Dordr)       Date:  2017-12-07       Impact factor: 6.730

Review 2.  Autocrine and paracrine purinergic signaling in the most lethal types of cancer.

Authors:  M Reyna-Jeldes; M Díaz-Muñoz; J A Madariaga; C Coddou; F G Vázquez-Cuevas
Journal:  Purinergic Signal       Date:  2021-05-12       Impact factor: 3.765

Review 3.  Targeting the purinergic pathway in breast cancer and its therapeutic applications.

Authors:  Julia Beatrice de Araújo; Vanessa Vitória Kerkhoff; Sarah Franco Vieira de Oliveira Maciel; Débora Tavares de Resende E Silva
Journal:  Purinergic Signal       Date:  2021-02-12       Impact factor: 3.765

4.  Identification of a prognostic gene signature of colon cancer using integrated bioinformatics analysis.

Authors:  Zhengyu Fang; Sumei Xu; Yiwen Xie; Wenxi Yan
Journal:  World J Surg Oncol       Date:  2021-01-13       Impact factor: 2.754

5.  2‑Cl‑IB‑MECA regulates the proliferative and drug resistance pathways, and facilitates chemosensitivity in pancreatic and liver cancer cell lines.

Authors:  Jana Kotulova; Katerina Lonova; Agata Kubickova; Jana Vrbkova; Pavla Kourilova; Marian Hajduch; Petr Dzubak
Journal:  Int J Mol Med       Date:  2022-01-18       Impact factor: 4.101

6.  Galectin-9 inhibits cell proliferation and induces apoptosis in Jurkat and KE-37 acute lymphoblastic leukemia cell lines via caspase-3 activation.

Authors:  Narges Zargar Balajam; Mahdi Shabani; Mahmoud Aghaei
Journal:  Res Pharm Sci       Date:  2021-10-15

7.  Mitochondrial and caspase pathways are involved in the induction of apoptosis by nardosinen in MCF-7 breast cancer cell line.

Authors:  Amirhosein Shahali; Mustafa Ghanadian; Seyyed Mehdi Jafari; Mahmoud Aghaei
Journal:  Res Pharm Sci       Date:  2018-02

8.  Adenosine deaminase inhibition suppresses progression of 4T1 murine breast cancer by adenosine receptor-dependent mechanisms.

Authors:  Barbara Kutryb-Zajac; Patrycja Koszalka; Paulina Mierzejewska; Alicja Bulinska; Magdalena A Zabielska; Karolina Brodzik; Aleksandra Skrzypkowska; Lukasz Zelazek; Iwona Pelikant-Malecka; Ewa M Slominska; Ryszard T Smolenski
Journal:  J Cell Mol Med       Date:  2018-10-05       Impact factor: 5.310

Review 9.  Purine-Metabolising Enzymes and Apoptosis in Cancer.

Authors:  Marcella Camici; Mercedes Garcia-Gil; Rossana Pesi; Simone Allegrini; Maria Grazia Tozzi
Journal:  Cancers (Basel)       Date:  2019-09-12       Impact factor: 6.639

Review 10.  GLI3: a mediator of genetic diseases, development and cancer.

Authors:  Stephan J Matissek; Sherine F Elsawa
Journal:  Cell Commun Signal       Date:  2020-04-03       Impact factor: 7.525

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.